One year after his arrest, PixarBio CEO Francis Reynolds was convicted of defrauding investors of $12.7 million.
Baxter International Inc. was named in a complaint for improperly marketing opioid drugs and revealed an internal probe into the medical supplier’s accounting, sending the company’s shares down.
A Missouri appeals court overturned a $110 million verdict against Johnson & Johnson in a lawsuit by a Virginia woman who says she developed ovarian cancer after decades of using of the company’s talc-based products for feminine hygiene.
Martin Shkreli will continue to reside in federal prison after the notorious “Pharma Bro” failed to win an appeal to his 2017 criminal conviction for securities fraud and conspiracy to commit fraud.
Catalyst Pharmaceuticals Inc., under fire for a high price tag on a rare disease drug, sued the U.S. Food and Drug Administration to challenge the recent approval of a lower-cost rival medicine.
Vaunted immunotherapy pioneers from the Dana-Farber Cancer Institute won a key court case that could be worth billions of dollars.
The Australian subsidiaries of British drugmaker GlaxoSmithKline and Swiss drugmaker Novartis misled customers and broke the law by promoting identical liniments as though they could treat specific ills, an Australian court found.
British drugmaker Vectura Group Plc won a patent infringement litigation case against GlaxoSmithKline Plc in the United States and was awarded $89.7 million in damages for the period from August 2016 through December 2018.
Generic competitors to British drugmaker Indivior Plc’s blockbuster opioid addiction treatment are on course to launch after the firm’s attempt to stay a U.S. District court judgement was rejected.
Edwards Lifesciences Corp. paid rival Boston Scientific Corp. $180 million as part of a settlement to end long-standing patent disputes between the two medical device makers.